^
    Back
    Association details:
    Biomarker:KRAS G12C + PD-L1 overexpression
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ELCC 2022
    Title:

    KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy

    Published date:
    03/23/2022
    Excerpt:
    LUADs harboring KRAS G12C mutations displayed higher frequency of tumors with PD-L1 ≥ 50% (n=7, 50%) and less PD-L1 negative tumors (n=1, 16.25%) compared with patients with KRAS non-G12C mutations...Survival analysis showed a trend towards a better OS in KRAS G12C tumors compared with tumors harboring KRAS non-G12C mutations...LUADs harboring KRAS G12C mutations with higher PD-L1 expression compared to other KRAS mutations and seem to benefit more from immunotherapy.
    DOI:
    10.1016/j.annonc.2022.02.199